• About
• Links
• Contact
• Sitemap
• 

Biomarkers in Drug Discovery - Optimizing Drug Discovery Timeline and Costs

Summary

The report provides an in-depth analysis of the potential applications of biomarkers in pharmaceutical drug discovery and clinical services. This pharmaceutical and healthcare report suggests investment decisions in biomarker-based drug research by providing information on valid biomarkers, pipelines, case studies, competitive landscape, geographical trends, mergers and acquisitions and market potential. It also provides an analysis on the trends prevailing in the global biomarkers market. In addition to this, the report covers drivers and restrains for the global biomarkers market.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis.

NOTE: 15% will be automatically deducted from the list price for orders placed before May 14th, 2010

Scope

The scope of this report includes:

Market Potential and Pipeline Analysis of biomarkers by phase of development, therapeutic class and geography.

Market Size and forecast of global biomarkers market and biomarkers drug discovery market from 2000 to 2008, forecast forward to 2015.

Analysis of Key geographies including the US (United States), Europe the UK (United Kingdom), France, Germany, Italy and Spain), Australia and Southeast Asia.

Investments and Funding Analysis for top companies (Quest Diagnostics, Applied Biosystems, Vermillion, BGMedical, Menarini, Abbott, Roche, Genetech, Affymetrix and Amgen) in the biomarker-based assay development arena. This includes biomarker research on the application and development of novel biomarkers by the top companies and analysis of the competitive factors affecting the global biomarkers market.

Qualitative analysis of market drivers, market trends, and challenges.

M&A landscape in the biomarkers space segmented by deal value, geography and phase.

Reasons to buy

The report will improve decision making and will enable you to:

Develop business strategies by understanding the trends and developments that are driving the biomarkers-based drug research and development.

Design, develop and expand your product development, marketing and sales strategies based on forecast of global biomarkers and biomarkers drug discovery market till 2015

Develop business strategies to exploit biomarkers-based drug discovery market in emerging geographies

Identify the key players positioned to take advantage of the emerging market opportunities

Exploit M&A opportunities by identifying key market players with the most novel pipeline

 

Table of Contents

 

1 Table of Contents 3

 

• 1.1 List of Tables 6
• 1.2 List of Figures 7

 

2 Biomarkers in Drug Discovery - Facilitating a Quick Turnaround Time: Overview 8

 

• 2.1 Introduction 8
• 2.2 Research Report Guidance 8
• 2.3 History of Biomarkers 9
• 2.4 Biomarker Discovery and the Validation Process 10
  • 2.4.1 Product Development Process from Discovery to Launch 11
• 2.5 General Application of Biomarkers 12
  • 2.5.1 Biomarkers in Drug Discovery and Drug Development 13
  • 2.5.2 Role of Biomarkers in the Drug Discovery Process 13
  • 2.5.3 Application of Biomarkers in Disease Diagnosis and Prognosis 13
  • 2.5.4 Potential Impact of Biomarkers on Disease States 15
  • 2.5.5 Population Genetics Study 15
  • 2.5.6 Environmental Health and Risk Assessment 17
  • 2.5.7 Role of Biomarkers in Environmental Health and Risk Assessment 17
  • 2.5.8 Toxicology Studies in Dietary Items or Nutraceuticals 18
• 2.6 Application of Biomarkers in Drug Discovery 18
  • 2.6.1 Lead Identification & Optimization 19
  • 2.6.2 Potential Role of Biomarkers in Lead Identification and Optimization 19
  • 2.6.3 Target Validation 20
  • 2.6.4 Toxicological Assay (Preclinical & Clinical) 20
  • 2.6.5 Mechanism of Action 20
  • 2.6.6 Monitor Therapy and Dose Response 21
  • 2.6.7 Stratify Patient Population 21
  • 2.6.8 Filing and Post Marketing Surveillance 21

 

3 Biomarkers in Drug Discovery - Case Studies 23

 

• 3.1 Vermillion’s Hepcidin Biomarker for Ovarian Oancer 23
  • 3.1.1 Definition 23
  • 3.1.2 Hepcidin Biomarker 23
  • 3.1.3 About Ovarian Cancer 23
  • 3.1.4 Company Profile 24
  • 3.1.5 Technology Used 25
  • 3.1.6 Market Information 25
  • 3.1.7 Advantages 25
  • 3.1.8 Future Prospect 26
• 3.2 Epigenomic’s Septin 9 Biomarker for Colorectal Cancer 26
  • 3.2.1 DNA Methylation 26
  • 3.2.2 Septin 9 27
  • 3.2.3 Septin Biomarker 27
  • 3.2.4 About Colorectal Cancer 27
  • 3.2.5 Advantages 27
  • 3.2.6 Future Perspective 28
  • 3.2.7 Clinical Study 28
  • 3.2.8 Company Profile 28
  • 3.2.9 Technology Overview 29
  • 3.2.10 Market Information 29
• 3.3 BiPar Science’s PARP 1 Gene Biomarker for Multiple Cancer Types 29
  • 3.3.1 PARP 1 Gene 29
  • 3.3.2 PARP 1 Inhibitors 30
  • 3.3.3 BSI-201 30
  • 3.3.4 TNBC (Triple Negative Breast Cancer) 31
  • 3.3.5 Technology 31
  • 3.3.6 Advantage 31
  • 3.3.7 Company Profile 31
  • 3.3.8 Market Information 31
  • 3.3.9 Clinical Study 31

 

4 Biomarkers in Drug Discovery – Market Characterization 33

 

• 4.1 Market Overview 33
• 4.2 Market Size and Forecasts 33
  • 4.2.1 Driver and Restraints 37
  • 4.2.2 Drivers for the Global Biomarkers Market 38
  • 4.2.3 Barriers for the Global Biomarkers Market 40
• 4.3 Unmet Needs - Biomarkers Fulfilling the Unmet Needs of Drug Discovery 40
  • 4.3.1 High Attrition Rates 41
  • 4.3.2 High Drug Discovery Cost 41
  • 4.3.3 Time consuming 42
  • 4.3.4 Safety and Efficacy 42
  • 4.3.5 Invasiveness, Selectivity and Sensitivity 42

 

5 Trends Analysis 43

 

• 5.1 Regulatory Landscape (Current and Future) 43
  • 5.1.1 Investigative/ Exploratory Biomarker 43
  • 5.1.2 Probable Valid Biomarker 43
  • 5.1.3 Known Valid Biomarker 43
  • 5.1.4 Regulatory Biomarker 43
• 5.2 Validated Biomarker 43
  • 5.2.1 Validated Biomarkers Applied by Top Pharmaceuticals Players in their FDA Approved Drugs 44
• 5.3 Regulatory Acceptance of Valid Biomarkers 45
• 5.4 Regulatory Guidance from the FDA, EMEA, and MHLW (Japan) 46

 

6 Technology Adoptions 47

 

• 6.1 Unmet Need - Drug Discovery 47
  • 6.1.1 Biomarkers Technology Exists to Fulfill Unmet Drug Discovery Needs 47
• 6.2 Increased Awareness Among Pharmaceutical and Research Sector 48
• 6.3 Increasing Adoption Due to Wide Application 48
• 6.4 Biomarkers’ Future - Drug Discovery Unmet Needs Fulfilled 48

 

7 Global Biomarkers Market– Competitive Landscape 49

 

• 7.1 Key Biomarkers Players 49
  • 7.1.1 Quest Diagnostics 50
  • 7.1.2 Applied Biosystems 51
  • 7.1.3 Vermillion 52
  • 7.1.4 BGMedical 53
  • 7.1.5 Menarini 54
  • 7.1.6 Abbott 55
  • 7.1.7 Roche 56
  • 7.1.8 Genentech 57
  • 7.1.9 Affymetrix 58
  • 7.1.10 Amgen 59
• 7.2 Global Biomarkers Market – Geographic Landscape 60

 

8 Biomarkers in Drug Discovery – Pipeline Analysis 62

 

• 8.1 Pipeline Analysis 62
  • 8.1.1 Pipeline analysis by Phase 65
  • 8.1.2 Pipeline Analysis – Therapeutic class 66
  • 8.1.3 Pipeline Analysis by Geography 67

 

9 Global Biomarkers market – Strategic Consolidations 68

 

• 9.1 Mergers and Acquisitions 68
  • 9.1.1 Thermo Fisher Scientific Inc. Merges with B.R.A.H.M.S. AG 68
  • 9.1.2 Clinical Data Inc to Acquire Avlon Pharmaceuticals 68
  • 9.1.3 OSI Pharmaceuticals and AVEO Enter Collaborative Alliance 68
  • 9.1.4 PEP Products Inc. and Interleukin Genetics Inc. Enter Collaborative Alliance 69
  • 9.1.5 Pfizer Canada signs Alliance Deal with the Centre of Excellence For The Prevention of Organ Failure (Proof) 69
  • 9.1.6 Millipore Corporation Acquires Guava Technologies 69
  • 9.1.7 SuperGen Inc. Acquires Montigen Pharmaceuticals, Inc. 69
  • 9.1.8 National Institute of Allergy and Infectious Diseases (NIAID) Enters Collaborative Alliance with Caprion Proteomics Inc. 69
  • 9.1.9 Entelos Inc Acquires Iconix Biosciences 69
  • 9.1.10 Vermillion Inc Acquires Ciphergen Biosystems 69
  • 9.1.11 Cleveland Biolabs, Inc. Enters Collaborative Alliance with CBMS-MITS JPMO 69
• 9.2 Mergers and Acquisition Analysis by Deal Type 70
• 9.3 Mergers and Acquisition by Year of Consolidations 71
• 9.4 Mergers and Acquisitions by Geography 72
• 9.5 Mergers and Acquisitions by Deal value 72

 

10 Appendix 74

 

• 10.1 Abbreviations 74
• 10.2 Research Methodology 74
  • 10.2.1 Coverage 75
  • 10.2.2 Secondary Research 75
  • 10.2.3 Primary Research 76
  • 10.2.4 Expert Panel Validation 76
• 10.3 Contact Us 76
• 10.4 Disclaimer 76

 

1.1 List of Tables

 

• Table 1: Biomarkers in Drug Discovery, Historical Revenue, Global Biomarkers Market, ($bn, 2000-2008) 33
• Table 2: Biomarkers in Drug Discovery, Historical Revenue, Global Biomarkers Market, ($bn, 2008-2015) 34
• Table 3: Biomarkers in Drug Discovery, Historical Revenue, Biomarker’s Drug Discovery Market Revenue ($bn), 2000-2008 34
• Table 4: Biomarkers in Drug Discovery, Historical Revenue, Global Biomarkers Drug Discovery Market Revenue ($bn), 2008-2015 34
• Table 5: Biomarkers in Drug Discovery, Historical Revenues, Biomarker’s Molecular Diagnostics Market Revenue ($bn), 2000-2008 35
• Table 6: Biomarkers in Drug Discovery, Historical Revenue, Biomarkers Molecular Diagnostics Market Revenue ($bn), 2008-2015 35
• Table 7: Biomarkers in Drug Discovery, Historical Revenue, Others Market Revenue ($bn), 2000-2008 36
• Table 8: Biomarkers in Drug Discovery, Historical Revenue, Others Market Revenue ($bn), 2008-2015 36
• Table 9: Biomarkers in Drug Discovery, Global, Regulatory Filings for Biomarkers, 2009 43
• Table 10: Biomarkers in Drug Discovery, Global, Validated Biomarkers Applied in FDA Approved Drugs, 2009 44
• Table 11: Biomarkers in Drug Discovery, Global,Biomarkers in Discovery Phase, 2009 62
• Table 12: Biomarkers in Drug Discovery, Global, Biomarkers in Preclinical Phase, 2009 64
• Table 13: Biomarkers in Drug Discovery, Global, Biomarkers in Phase I, 2009 65
• Table 14: Biomarkers in Drug Discovery, Global, Biomarkers in Phase II, 2009 65
• Table 15: Biomarkers in Drug Discovery, Global, Biomarkers in Phase III, 2009 65
• Table 16: Biomarkers in Drug Discovery, Global, Merger and Acquisitions, 2009 68

 

1.2 List of Figures

 

• Figure 1: Biomarkers in Drug Discovery, Global, History of Biomarkers, 2009 10
• Figure 2: Biomarkers in Drug Discovery, Global, Biomarker Discovery and Validation Process, 2009 11
• Figure 3: Biomarkers in Drug Discovery, Global, General Application of Biomarkers, 2010 12
• Figure 4: Biomarkers in Drug Discovery, Global, Application of Biomarkers in Diagnosis, 2009 14
• Figure 5: Biomarkers in Drug Discovery, Global, Potential Impact of Biomarkers on Disease States, 2009 15
• Figure 6: Biomarkers in Drug Discovery, Global, Application of Biomarkers in Population Genetic Studies, 2009 16
• Figure 7: Biomarkers in Drug Discovery, Global, Role of Biomarkers in Risk Assessment, 2009 17
• Figure 8: Biomarkers in Drug Discovery, Global, Biomarkers Accelerate the Drug Discovery Process, 2009 19
• Figure 9: Biomarkers in Drug Discovery, Global, Adoption of Biomarkers by Top Companies in Drug Discovery, 2009 21
• Figure 10: Biomarkers in Drug Discovery, Global, Case Studies, 2009 23
• Figure 11: Biomarkers in Drug Discovery, Global, Hepicidine Biomarker Case Study, 2009 24
• Figure 12: Biomarkers in Drug Discovery, Global, Septin 9 Biomarker Case Study, 2009 26
• Figure 13: Biomarkers in Drug Discovery, Global, PARP1 Gene Biomarker Case Study, 2009 30
• Figure 14: Biomarkers in Drug Discovery, Global, Global Biomarkers Market Revenues ($bn), 2000-2015 33
• Figure 15: Biomarkers in Drug Discovery, Global, Biomarker’s Drug Discovery Market Revenues ($bn), 2000-2015 34
• Figure 16: Biomarkers in Drug Discovery, Historical Revenue, Biomarkers Molecular Diagnostics Market Revenue ($bn), 2000-2008 35
• Figure 17: Biomarkers in Drug Discovery, Global, Others Market Revenues ($bn), 2000-2015 36
• Figure 18: Biomarkers in Drug Discovery, Global, Global Biomarkers Market Segmentation, 2009 37
• Figure 19: Biomarkers in Drug Discovery, Global, Market Drivers and Restrains, 2009 37
• Figure 20:Biomarkers in Drug Discovery, Global, Integration of ‘Omics’ Drive Global Biomarker Market, 2009 39
• Figure 21: Biomarkers in Drug Discovery, Global, Biomarkers Fulfill Unmet Needs of Conventional Drug Discovery Methods, 2009 41
• Figure 22: Biomarkers in Drug Discovery, Global, Validated Biomarkers Applied by Pharmaceutical Companies in Drug Discovery, 2009 45
• Figure 23: Biomarkers in Drug Discovery, Global, Biomarkers Technology Adoption Framework, 2009 47
• Figure 24: Biomarkers in Drug Discovery, Global, Company Profile - Quest Diagnostics, 2009 50
• Figure 25: Biomarkers in Drug Discovery, Global, Company Profile - Applied Biosystems, 2009 51
• Figure 26: Biomarkers in Drug Discovery, Global, Company Profile - Vermillion, 2009 52
• Figure 27: Biomarkers in Drug Discovery, Global, Company Profile- BGMedical, 2009 53
• Figure 28: Biomarkers in Drug Discovery, Global, Company Profile - Menarini, 2009 54
• Figure 29: Biomarkers in Drug Discovery, Global, Company Profile- Abbott, 2009 55
• Figure 30: Biomarkers in Drug Discovery, Global, Company Profile-Roche, 2009 56
• Figure 31: Biomarkers in Drug Discovery, Global, Company Profile-Genentech, 2009 57
• Figure 32: Biomarkers in Drug Discovery, Global, Company Profile- Affymetrix, 2009 58
• Figure 33: Biomarkers in Drug Discovery, Global, Company Profile- Amgen, 2009 59
• Figure 34: Biomarkers in Drug Discovery, Global, Geographic Landscape-Global Biomarkers Market, 2009 60
• Figure 35: Biomarkers in Drug Discovery, Global, Pipeline Analysis by Phase, 2009 65
• Figure 36: Biomarkers in Drug Discovery, Global, Pipeline Analysis by Therapeutic Class, 2009 66
• Figure 37: Biomarkers in Drug Discovery, Global, Pipeline Analysis by Geography, 2009 67
• Figure 38: Biomarkers in Drug Discovery, Global, Global Biomarkers Market – Deal Analysis, 2009 70
• Figure 39: Biomarkers in Drug Discovery, Global, Mergers and Acquisition by Year of Consolidation, 2009 71
• Figure 40: Biomarkers in Drug Discovery, Global, Mergers and Acquisitions – Geographical Distribution, 2009 72
• Figure 41: Biomarkers in Drug Discovery, Global, Mergers and Acquisitions – Deal Value ($m), 2009 72
• Figure 42: Research Methodology 75

Other users found this report page using the following search terms: biomarker drug biomarkers discovery timeline biomarker market pharmaceutical development timelines cost

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.

Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.